GRI Bio (NASDAQ:GRI) Earns “Buy” Rating from HC Wainwright

GRI Bio (NASDAQ:GRI)‘s stock had its “buy” rating reissued by analysts at HC Wainwright in a report issued on Wednesday,Benzinga reports. HC Wainwright also issued estimates for GRI Bio’s Q2 2025 earnings at ($1.39) EPS, Q3 2025 earnings at ($0.75) EPS, Q4 2025 earnings at ($0.22) EPS, FY2025 earnings at ($2.30) EPS, FY2026 earnings at ($0.78) EPS, FY2027 earnings at ($0.44) EPS and FY2028 earnings at ($0.35) EPS.

Separately, Ascendiant Capital Markets lowered their price target on GRI Bio from $40.00 to $34.00 and set a “buy” rating on the stock in a research report on Tuesday, May 27th.

GRI Bio Stock Down 7.1%

GRI traded down $0.10 during trading hours on Wednesday, reaching $1.30. 111,953 shares of the company’s stock traded hands, compared to its average volume of 291,265. The firm has a 50-day moving average price of $1.50 and a 200 day moving average price of $6.98. GRI Bio has a 52-week low of $1.10 and a 52-week high of $59.34. The firm has a market capitalization of $2.78 million, a PE ratio of -0.11 and a beta of -1.68.

GRI Bio (NASDAQ:GRI) last issued its quarterly earnings data on Thursday, May 15th. The company reported ($5.80) earnings per share for the quarter, missing analysts’ consensus estimates of ($4.08) by ($1.72). Equities analysts predict that GRI Bio will post -3.04 EPS for the current fiscal year.

Institutional Inflows and Outflows

A hedge fund recently raised its stake in GRI Bio stock. Geode Capital Management LLC boosted its stake in GRI Bio, Inc. (NASDAQ:GRI) by 543.0% during the 4th quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The firm owned 76,182 shares of the company’s stock after acquiring an additional 64,335 shares during the period. Geode Capital Management LLC owned 0.85% of GRI Bio worth $63,000 as of its most recent SEC filing. 33.95% of the stock is owned by institutional investors and hedge funds.

GRI Bio Company Profile

GRI Bio, Inc, a clinical-stage biopharmaceutical company, focuses on treating inflammatory, fibrotic, and autoimmune diseases in the United States. Its product pipeline comprises GRI-0621, which is in phase II clinical development for the treatment of idiopathic pulmonary fibrosis; GRI-0803 which is in phase I trial for the treatment of systematic lupus erythematosus; GRI-0124, which is in pre-clinical development for the treatment of primary sclerosing cholangitis; and GRI-0729 in pre-clinical development.